Solutions
ASOs for Rare Disease
Jump To:
Overview
ASOs built for programs where continuity, speed & rigor matter
Rare disease antisense oligonucleotide (ASO) programs operate under constraints that standard development models don’t accommodate: small batches, compressed timelines, and no tolerance for downstream rework.
Success depends on partners who understand not just how to make oligonucleotides — but how early decisions affect CMC, tox, and clinical readiness later.
Oligo Factory delivers where rare disease ASO programs demand it most.
BENEFITS & Support
ASOs Designed for Your Program’s Goals
- Preserve continuity across development stages
From early research material through tox and first GMP, without forcing resets or comparability exercises. - Move quickly without creating downstream CMC risk
Fast turnaround that remains aligned with rising regulatory expectations. - Execute small-batch manufacturing with rigor and reproducibility
Processes, analytics, and controls appropriate for very small quantities - Operate confidently in atypical, highly constrained development paths
Including ultra-rare and n-of-1 programs where timelines, materials, and decision are uniquely constrained
Rare Disease Program Support
If your program depends on small-batch material, fast TAT, and confidence that today’s work won’t limit tomorrow’s options, Oligo Factory is built to support you by combining speed with discipline – by design.
- Platform continuity from RUO through GMP: Sequences, chemistries, processes, and analytics are developed with GMP expectations in mind
- Purpose-built small-batch synthesis aligned to tox and early clinical needs: Optimized for turnaround time and reproducibility at the scales rare disease programs demand.
- Deep ASO chemistry and impurity-control expertise: Anticipating impurity and comparability challenges early, before they become limiting.
- Experience executing ultra-rare and n-of-1 programs: Including timeline-driven and highly constrained development paths.
- High-touch technical engagement: Dedicated project manager, with quick access to subject matter expertise without transactional handoffs.
Ideally Suited for…
- Rare disease biotech and therapeutic teams managing early ASO programs
- CMC leaders responsible for minimizing downstream risk
- Academic translational groups advancing ASOs toward clinical readiness
- Foundations supporting patient-driven and ultra-rare initiatives
Partnership in rare disease
A Trusted Partner in Ultra-Rare ASO Development
Oligo Factory is a proud manufacturing partner to n-Lorem Foundation, supporting patient-driven, n-of-1 ASO programs where execution, quality, and turnaround time are critical.
These same principles applied across all rare disease programs Oligo Factory supports: fit-for-purpose rigor, disciplined flexibility, and continuity across stages.
